ATE186647T1 - Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden - Google Patents
Zellulare abgabesystem mit cyclodextrin, für oligonukleotidenInfo
- Publication number
- ATE186647T1 ATE186647T1 AT95922923T AT95922923T ATE186647T1 AT E186647 T1 ATE186647 T1 AT E186647T1 AT 95922923 T AT95922923 T AT 95922923T AT 95922923 T AT95922923 T AT 95922923T AT E186647 T1 ATE186647 T1 AT E186647T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclodextrin
- oligonucleotides
- oligonucleotide
- delivery system
- methods
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 6
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000001413 cellular effect Effects 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 abstract 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 230000004700 cellular uptake Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25207294A | 1994-06-01 | 1994-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE186647T1 true ATE186647T1 (de) | 1999-12-15 |
Family
ID=22954476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95922923T ATE186647T1 (de) | 1994-06-01 | 1995-06-01 | Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US5691316A (de) |
| EP (1) | EP0762898B1 (de) |
| JP (1) | JPH10501237A (de) |
| CN (1) | CN1158088A (de) |
| AT (1) | ATE186647T1 (de) |
| AU (1) | AU2764395A (de) |
| CA (1) | CA2191777A1 (de) |
| DE (1) | DE69513395T2 (de) |
| DK (1) | DK0762898T3 (de) |
| ES (1) | ES2139904T3 (de) |
| GR (1) | GR3032355T3 (de) |
| WO (1) | WO1995032739A1 (de) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030099959A1 (en) * | 1995-04-12 | 2003-05-29 | Kandimalla Ekambar R. | Cooperative oligonucleotides |
| US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| AU2669599A (en) * | 1998-02-12 | 1999-08-30 | Regents Of The University Of California, The | Compositions for receptor/liposome mediated transfection and methods of using same |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| RU2243236C2 (ru) * | 1998-07-01 | 2004-12-27 | Кэлифорниа Инститьют Оф Текнолоджи | Линейные сополимеры циклодекстрина |
| US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
| AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
| US6716589B2 (en) | 2000-11-20 | 2004-04-06 | Alphabeta Ab | Discordant helix stabilization for prevention of amyloid formation |
| TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| WO2003052117A2 (en) * | 2001-09-19 | 2003-06-26 | Massachusetts Institute Of Technology | Methods and products related to non-viral transfection |
| US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
| AU2002368202B2 (en) * | 2001-11-02 | 2008-06-05 | Insert Therapeutics, Inc | Methods and compositions for therapeutic use of RNA interference |
| CA2428740A1 (en) * | 2002-05-20 | 2003-11-20 | Bayer Corporation | Automated method and reagent therefor for assaying body fluid samples such as cerebrospinal fluid (csf) |
| EP2277551B1 (de) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel |
| WO2004032862A2 (en) * | 2002-10-09 | 2004-04-22 | Insert Therapeutics, Inc. | Cyclodextrin-based materials, compositions and uses related thereto |
| US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
| US20050147584A1 (en) * | 2004-01-05 | 2005-07-07 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
| WO2004080406A2 (en) | 2003-03-07 | 2004-09-23 | Alnylam Pharmaceuticals | Therapeutic compositions |
| WO2004094345A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | Protected monomers |
| US20070179100A1 (en) * | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
| JP4597976B2 (ja) | 2003-04-17 | 2010-12-15 | アルナイラム ファーマシューティカルズ インコーポレイテッド | 修飾ｉＲＮＡ剤 |
| CA2542232A1 (en) | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals, Inc. | Method for treating neurodegenerative disease by inhibiting alpha-synuclein |
| US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
| US7883688B2 (en) * | 2005-02-03 | 2011-02-08 | Agency For Science, Technology And Research | Polycationic polyrotaxanes capable of forming complexes with nucleic acids |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| CA2732229C (en) * | 2008-07-25 | 2023-10-17 | Alnylam Pharmaceuticals, Inc. | Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand |
| US20100056612A1 (en) * | 2008-08-06 | 2010-03-04 | Alexander Chucholowski | Molecular entities for binding, stabilization and cellular delivery of charged molecules |
| CN102317472A (zh) * | 2008-12-12 | 2012-01-11 | 欧洲基因技术股份有限公司 | 使用环糊精改进核酸扩增反应的特异性、灵敏度和产率 |
| WO2010088282A1 (en) * | 2009-01-30 | 2010-08-05 | Rgo Biosciences Llc | Nucleic acid binding assays |
| EP2503888A4 (de) * | 2009-11-23 | 2015-07-29 | Cerulean Pharma Inc | Polymere auf cyclodextrinbasis zur therapeutischen verabreichung |
| WO2011097138A1 (en) * | 2010-02-04 | 2011-08-11 | Rgo Bioscience Llc | Molecular entities for binding, stabilization and cellular delivery of negatively charged molecules |
| WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
| KR20140026396A (ko) | 2011-03-08 | 2014-03-05 | 어섹스 팔마큐티칼스 인코포레이티드 | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 |
| GB201216387D0 (en) | 2012-09-13 | 2012-10-31 | Ge Healthcare Uk Ltd | Solid matrix for one step nucleic acid amplification |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| KR101465365B1 (ko) * | 2013-10-15 | 2014-11-25 | 성균관대학교산학협력단 | 리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법 |
| EP3484908A4 (de) | 2016-07-15 | 2020-04-08 | AM Chemicals Llc | Nicht-nukleosidische feste träger und phosphoramiditbausteine für die oligonukleotidsynthese |
| US20190177800A1 (en) * | 2017-12-08 | 2019-06-13 | 10X Genomics, Inc. | Methods and compositions for labeling cells |
| US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| JP2021525086A (ja) * | 2018-05-30 | 2021-09-24 | アクソーラボズ ゲーエムベーハー | オリゴヌクレオチドコンジュゲートを検出するための方法 |
| CN114874358B (zh) * | 2022-04-11 | 2023-05-02 | 上海师范大学 | 一种多核铈纳米材料的合成方法及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| ATE129897T1 (de) * | 1988-07-07 | 1995-11-15 | Univ Pennsylvania | Modulation von virus-wirtszell-wechselwirkungen unter verwendung von cyclischen oligosacchariden. |
| WO1991002040A1 (en) * | 1989-08-04 | 1991-02-21 | Kosak Kenneth M | Cyclodextrin labels for nucleic acid and biochemical analysis |
| US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| JPH05170650A (ja) * | 1991-12-19 | 1993-07-09 | Sanyo Kokusaku Pulp Co Ltd | 医薬組成物およびその製造方法 |
| WO1993023570A1 (en) * | 1992-05-11 | 1993-11-25 | Pharmagenics, Inc. | Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety |
| US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
| US5457187A (en) * | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
-
1994
- 1994-11-17 US US08/341,522 patent/US5691316A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 CN CN95194366A patent/CN1158088A/zh active Pending
- 1995-06-01 AT AT95922923T patent/ATE186647T1/de not_active IP Right Cessation
- 1995-06-01 WO PCT/US1995/006916 patent/WO1995032739A1/en not_active Ceased
- 1995-06-01 CA CA002191777A patent/CA2191777A1/en not_active Abandoned
- 1995-06-01 DE DE69513395T patent/DE69513395T2/de not_active Expired - Fee Related
- 1995-06-01 DK DK95922923T patent/DK0762898T3/da active
- 1995-06-01 EP EP95922923A patent/EP0762898B1/de not_active Expired - Lifetime
- 1995-06-01 AU AU27643/95A patent/AU2764395A/en not_active Abandoned
- 1995-06-01 JP JP8501182A patent/JPH10501237A/ja not_active Withdrawn
- 1995-06-01 ES ES95922923T patent/ES2139904T3/es not_active Expired - Lifetime
- 1995-06-07 US US08/480,833 patent/US5605890A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,834 patent/US5616565A/en not_active Expired - Lifetime
-
2000
- 2000-01-13 GR GR20000400052T patent/GR3032355T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5605890A (en) | 1997-02-25 |
| AU2764395A (en) | 1995-12-21 |
| ES2139904T3 (es) | 2000-02-16 |
| CN1158088A (zh) | 1997-08-27 |
| GR3032355T3 (en) | 2000-04-27 |
| US5616565A (en) | 1997-04-01 |
| EP0762898B1 (de) | 1999-11-17 |
| DE69513395D1 (de) | 1999-12-23 |
| DE69513395T2 (de) | 2000-07-27 |
| US5691316A (en) | 1997-11-25 |
| JPH10501237A (ja) | 1998-02-03 |
| DK0762898T3 (da) | 2000-04-25 |
| EP0762898A1 (de) | 1997-03-19 |
| WO1995032739A1 (en) | 1995-12-07 |
| CA2191777A1 (en) | 1995-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69513395D1 (de) | Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden | |
| NZ334190A (en) | Method for improved selectivity in photo-activation of molecular agents | |
| DE69835201D1 (en) | Neoglycoproteine | |
| DE69334082D1 (de) | Desinfizierendes Jod-Harz, Verfahren zu seiner Herstellung und Verwendung in textilen Kombinationen | |
| ATE263579T1 (de) | Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel | |
| ATE359825T1 (de) | J-kette und analoge für konjugate zielgerichtet auf epithelzellen | |
| ATE237312T1 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
| CY1109437T1 (el) | ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ | |
| CY1110590T1 (el) | Επιλεκτικος ως προς την αλληλουχια dna-ανασυνδυασμος σε ευκαρυωτικα κυτταρα | |
| TR199901949T2 (xx) | Lemfositik t�m�rler i�in �areler. | |
| IL146125A0 (en) | Novel quinones as disease therapies | |
| DE50014532D1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| ATE338553T1 (de) | Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin | |
| ATE196083T1 (de) | Verwendung von ferrioxamin-b zur behandlung septischen schocks | |
| DK0841912T3 (da) | 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning | |
| MY134896A (en) | Therapeutic agent for hepatitis | |
| PT768886E (pt) | Efeitos de revestimento endotelial e tratamento de desordens vasospasticas | |
| ATE291586T1 (de) | Humanes antibiotisches protein | |
| PL373511A1 (en) | Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use | |
| PT1054680E (pt) | Tratamento do cancro da bexiga pela parede celular de mycobacterium phlei | |
| DE50007818D1 (de) | Komplexierung von rns, insbesondere von ribozymen, mit polyethyleniminen zu deren stabilisierung und zellulären einschleusung | |
| IT1290910B1 (it) | 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive | |
| FI933506L (fi) | Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaatteja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina | |
| ATE396742T1 (de) | Komplexe mit adjuvanter wirkung | |
| CY1107455T1 (el) | Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |